FY27

Biocon Q1 FY27 Revenue Rises 10% to Rs 4,336 Crore as Biopharma Business Leads Growth

By BiotechReality Business Intelligence Desk
6 August 2026

Biocon Limited posted a 10% YoY rise in Q1 FY27 consolidated revenue to Rs 4,336 crore, powered by 17% biopharma growth, a 349% jump in net profit, and continued biosimilar launches across the US and Canada.

News Business Healthcare & Pharmaceuticals

Sun Pharma Q1FY27 Results: Sales Rise 10.1% to Rs1,518 Mn

By BiotechReality Business Intelligence Desk
3 August 2026

Sun Pharma’s Q1FY27 results show consolidated sales up 10.1% to Rs. 151,836 million, net profit at Rs. 28,948 million, and 16% growth in India Formulations, as the Organon acquisition clears a key shareholder milestone ahead of an early-2027 close.

Tag: FY27

Biocon Q1 FY27 Revenue Rises 10% to Rs 4,336 Crore as Biopharma Business Leads Growth

Sun Pharma Q1FY27 Results: Sales Rise 10.1% to Rs1,518 Mn

Areas Covered

Discover More

Merck KGaA CDMO Divestment: Lonza to Acquire Life Science CDMO Business for Mid-Triple-Digit Million Euros

AstraZeneca Q3 2026 Results: Total Revenue Rises 7% to $46.9bn as Oncology Leads Growth and FY2026 Guidance Holds

AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises

Merck Daejeon Bioprocessing Center Opens With €300 Million Investment to Expand Asia-Pacific Biologics Supply

Sandoz 2026 Sales Rise 5% at CC as Biosimilars Climb 19%; Core-EBITDA Margin Guidance Upgraded to 23.0-23.5%

Novartis Q3 2026 Results: Kisqali and Kesimpta Lift Sales as Novartis Raises Full-Year Core Operating Income Guidance